Johnson & Johnson launches 'Gut Tunnel' in Singapore to spotlight endoscopic remission in IBD.

Johnson & Johnson has launched the interactive 'Gut Tunnel' experience in Singapore, along with educational programs across the Asia Pacific, to empower people living with inflammatory bowel disease (IBD) to pursue endoscopic remission, a critical yet under-recognized treatment goal, as part of its ongoing Dual Control campaign.

MD, PhD, President of the Korean Association for the Study of Intestinal Diseases, Korea, Sung-Ae Jung said Decades of innovation have advanced IBD care. Endoscopic remission is now the long-term treatment goal for IBD, and it indicates deeper healing and drives better patient outcomes.

According to Towards Healthcare, the Gastrointestinal Endoscopy Market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 44.54 billion in 2026 to approximately USD 88.3 billion by 2035, representing a compound annual growth rate (CAGR) of 7.9% from 2026 to 2035. Growth is driven by the increased incidence of gastrointestinal diseases, peptic ulcers, and colorectal cancer, necessitating early and frequent diagnostic and therapeutic endoscopies. The integration of Artificial Intelligence (AI) and advanced imaging in videoscopes enhances diagnostic accuracy and early detection of lesions.

About Johnson & Johnson

Johnson & Johnson is a leading American multinational corporation that develops, manufactures, and sells healthcare products. It Operate at global with J&J research and develops treatments for complex conditions, including oncology, immunology, neuroscience, and cardiopulmonary diseases.

The company serves the local healthcare needs through localized pharmaceutical and medical device operations, and frequently adjusts to regulatory changes to make healthcare more affordable.

Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions to deliver the breakthroughs that profoundly impact health for humanity.
A recent report by Towards Healthcare highlights that the gastrointestinal endoscopy market is witnessing growth driven by the rising prevalence of GI disorders, advancements in AI, and a high demand for minimally invasive procedures, fueled by rising healthcare infrastructure spending and changing lifestyle habits. This presents a massive opportunity to eliminate sterilization costs and reduce the risk of cross-contamination in clinics and hospitals. AI integration enhances polyp detection during colonoscopies and increases the overall diagnostic accuracy of the GI tract.